Back to top
more

Chimerix (CMRX)

(Delayed Data from NSDQ)

$0.86 USD

0.86
319,709

-0.02 (-1.72%)

Updated Sep 13, 2024 04:00 PM ET

After-Market: $0.86 +0.01 (0.58%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Kinjel Shah headshot

Monkeypox Fears Drive Smallpox Antiviral Makers Higher

Emergent BioSolutions (EBS) stock was up almost 12% while SIGA Technologies (SIGA) rose 17.1% on Thursday.

Biotech Stock Roundup: BBIO Up on BMY Deal, GILD & CMRX Offer Updates

Regulatory updates and acquisition news from Bristol Myers' (BMY) and BridgeBio Pharma (BBIO) are a few key highlights from the biotech sector during the past week.

Chimerix (CMRX) Plunges on Unfavorable Pipeline Updates

The development of Chimerix's (CMRX) lead candidate, ONC201, gets delayed as the FDA states that data from the retrospective study is unlikely to support an approval. The company ends the DSTAT program.

Chimerix (CMRX) Reports Q4 Loss, Lags Revenue Estimates

Chimerix (CMRX) delivered earnings and revenue surprises of -309.09% and 99.90%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Vapotherm (VAPO) Reports Q4 Loss, Tops Revenue Estimates

Vapotherm (VAPO) delivered earnings and revenue surprises of -14.52% and 2.04%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Chimerix (CMRX) Report Negative Q4 Earnings? What You Should Know

Chimerix (CMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Chimerix (CMRX) Reports Q3 Loss, Lags Revenue Estimates

Chimerix (CMRX) delivered earnings and revenue surprises of 0.00% and -72.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Chimerix (CMRX) to Report a Decline in Earnings: What to Look Out for

Chimerix (CMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Chimerix (CMRX) Sees Hammer Chart Pattern: Time to Buy?

Chimerix (CMRX) has been struggling lately, but the selling pressure may be coming to an end soon

Owens & Minor (OMI) to Report Q1 Earnings: What's in Store?

Owens & Minor (OMI) witnesses rebound in demand for elective procedures through the months of Q1.

Company News for Jan 11, 2021

Companies in the news are: CMRX, GSAT, MRUS, FFIV

Chimerx's (CMRX) NDA for Brincidofovir Accepted by FDA

Chimerix's (CMRX) NDA for brincidofovir as a medical countermeasure for smallpox has been accepted by the FDA.

Chimerix (CMRX) Reports Q2 Loss, Tops Revenue Estimates

Chimerix (CMRX) delivered earnings and revenue surprises of 11.11% and 19.83%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Chimerix (CMRX) Reports Q1 Loss, Lags Revenue Estimates

Chimerix (CMRX) delivered earnings and revenue surprises of -13.33% and -17.27%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

All You Need to Know About Chimerix (CMRX) Rating Upgrade to Buy

Chimerix (CMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Has Chimerix (CMRX) Outpaced Other Medical Stocks This Year?

Is (CMRX) Outperforming Other Medical Stocks This Year?

Chimerix (CMRX) Reports Q2 Loss, Lags Revenue Estimates

Chimerix (CMRX) delivered earnings and revenue surprises of -105.88% and -37.48%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Chimerix (CMRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Chimerix (CMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Chimerix to Surge Higher?

As of late, it has definitely been a great time to be an investor Chimerix.

Chimerix (CMRX) Reports Q1 Loss, Tops Revenue Estimates

Chimerix (CMRX) delivered earnings and revenue surprises of 0.00% and 17.80%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Chimerix (CMRX) Report Negative Q1 Earnings? What You Should Know

Chimerix (CMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Overall Growth Aid Thermo Fisher's (TMO) Q4 Earnings?

Thermo Fisher (TMO) rides high on a steadily strong analytical instrument business, flaunting robust global demand.

Can Solid Consumables Drive Illumina's (ILMN) Q4 Earnings?

Illumina's (ILMN) management is optimistic about witnessing solid demand across the NovaSeq portfolio, which also includes the S2 and S1 flow cells.

What Lies Ahead for Abbott (ABT) Stock This Earnings Season?

Abbott (ABT) is showing a steady rise on a healthy growth graph within its Diabetes Care business for a considerable period.

4 Medical Product Stocks Likely to Top Q4 Earnings Estimates

Given the encouraging performance of the medical products industry for most part of 2018, it will be interesting see how the constituent companies perform in Q4.